There is an increased risk of oral health complications for patients prescribed anti-resorptive or anti-angiogenic drugs (medication-related osteonecrosis of the jaw, MRONJ). This guidance provides recommendations, advice and information to help dental practitioners manage the routine dental care of patients prescribed these drugs and is an update to the previous SDCEP Oral Health Management of Patients Prescribed Bisphosphonates guidance.
The guidance is aimed primarily at dentists in primary care dental practice and will also be of relevance to the secondary care dental service, those involved in dental education and undergraduate trainees. The guidance is also of relevance to prescribers and dispensers of bisphosphonates and to patients.
Downloads
- Full Guidance – provides comprehensive background information, recommendations and practical advice. An accessible version (Word) is also available.
- Guidance in Brief – summarises the main recommendations from the full guidance. An accessible version (Word) is also available.
- Guidance for Prescribers and Dispensers – highlights the recommendations relevant to those who prescribe and dispense anti-resorptive and anti-angiogenic drugs. An accessible version (Word) is also available.